3-d Matrix logo

3-d Matrix(OTC) DMTRF

Market Cap$345.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-95%
5 Year+21%
1 Year+80%
1 Month+8%
$2.70
+3.72%
+0.10Today
3-d Matrix last closing stock price
MetricPriceDate
Last closeUSD 2.702026-10-01
3-d Matrix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8%USD 2.502026-07-20
1 month+8%USD 2.502026-07-20
3 month+20%USD 2.252026-06-15
Year to date+13.92%USD 2.372025-12-12
1 year+80%USD 1.502025-09-30
3 year+143.24%USD 1.112023-07-13
5 year+21.08%USD 2.232021-09-27
Since inception-94.84%USD 52.352013-06-19

3-d Matrix Financials at a Glance

Market Cap

$345.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

¥12.00B

Net Income (TTM)

¥3.70B

EPS (TTM)

$0.18

P/E Ratio

14.08

Dividend

$0.00

Beta (Volatility)

-0.18 (Low)

Price

$2.70

Volume

7,330

Open

$2.78

Previous Close

$2.70

Daily Range

$2.70 - $2.78

52-Week Range

$1.50 - $3.96

Estimated Earnings Date

Dec 15, 2026

DMTRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 3-d Matrix

3-D Matrix, Ltd. is a biotechnology company based in Tokyo, Japan, specializing in self-assembling peptide technology. The company’s flagship product, PuraMatrix, is a versatile peptide hydrogel used in various medical applications, including regenerative medicine and drug delivery.

Products and Services
  • PuraMatrix: A self-assembling peptide hydrogel for medical applications
  • Innovative solutions for regenerative medicine and cell-based therapies
  • Advanced drug delivery mechanisms for surgical applications
Growth Outlook
  • Recent quarterly revenue reached JPY 3.31 billion, showcasing strong demand
  • Net income for Q1 2026 was JPY 310.86 million, indicating profitability
  • Operating income margin of 15.3% reflects efficient cost management
Financial Highlights
  • Trailing twelve months (TTM) revenue of JPY 12.5 billion demonstrates consistent growth
  • Net profit margin of 30.99% highlights strong profitability
  • Current ratio of 4.08 indicates robust liquidity position
3-D Matrix, Ltd. has established itself as a leader in peptide technology, with a focus on innovative medical solutions. The company's financial performance reflects a solid growth trajectory, supported by a strong product offering and efficient operations. The recent quarterly results indicate a healthy demand for its products, positioning the company favorably for future expansion. With a strong balance sheet and a commitment to research and development, 3-D Matrix is well-positioned to capitalize on opportunities in the biotechnology sector.
AI Generated • Sep 27, 2026

Industry

Biotechnology

Sector

Health Care

Employees

129

Website

www.3d-matrix.co.jp

Headquarters

Tokyo, TY 102-0083, JP

DMTRF Financials

Key Financial Metrics (TTM)

Gross Margin

79.52%

Operating Margin

15.28%

Net Income Margin

30.99%

Return on Equity

63.82%

Return on Capital

18.06%

Return on Assets

39.28%

Earnings Yield

7.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$345.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

127.98M

Volume

7.33K

Avg. Volume

150.891

Financials (TTM)

Gross Profit

¥9.54B

Operating Income

¥1.83B

EBITDA

¥2.55B

Operating Cash Flow

¥0.00

Capital Expenditure

¥0.00

Free Cash Flow

¥0.00

Cash & ST Invst.

¥1.68B

Total Debt

¥596.53M

3-d Matrix Performance Analysis

3-d Matrix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-04-30JPY 17,010,68228.4%
20242024-04-30JPY 31,386,92884.5%
20252025-04-30JPY 45,716,65345.7%
20262026-04-30JPY 71,678,70156.8%
3-d Matrix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-10-3119.2%
Q32026-01-31-2.9%
Q42026-04-3039.3%
Q12026-07-31-6.4%
3-d Matrix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-04-30JPY -0.30-8.7%
20242024-04-30JPY -0.02-92.0%
20252025-04-30JPY -0.17598.3%
20262026-04-30JPY 0.20N/A
3-d Matrix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-10-3115.3%
Q32026-01-31-40.1%
Q42026-04-30225.5%
Q12026-07-31-82.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

¥3.31B

+50.8%

Gross Profit

¥2.65B

+58.0%

Gross Margin

80.07%

N/A

Market Cap

$345.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.68M

N/A

Employees

129

N/A

Net Income

¥310.86M

-59.4%

EBITDA

¥507.89M

+5543.3%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

¥1.68B

+12.8%

Total Debt

¥596.53M

-74.3%

Accounts Receivable

¥2.89B

+43.0%

Inventory

¥3.73B

+53.6%

Long Term Debt

¥0.00

-100.0%

Short Term Debt

¥596.53M

+98.8%

Return on Assets

39.28%

N/A

Return on Invested Capital

25.12%

N/A

Free Cash Flow

¥0.00

N/A

Operating Cash Flow

¥0.00

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AONCAmerican Oncology Network, Inc.
$11.00+10.00%
CMVLFCellectis S.A.
$3.47+12.66%
EDTXFSpectral Medical Inc
$0.81-0.49%
ABTIAlterola Biotech, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$13.29+4.98%
HYGiShares Trust - iShares iBoxx $ High Yieldorate Bond ETF
$76.90+0.04%
NKENike
$35.15-0.71%
INTCIntel
$120.00-0.19%

Questions About DMTRF

What is the current price of 3-d Matrix?

3-d Matrix is trading at $2.70 per share.

What is the 52-week range for 3-d Matrix?

Over the past 52 weeks, 3-d Matrix has traded between $1.50 and $3.96.

How much debt does 3-d Matrix have?

As of the most recent reporting period, 3-d Matrix reported total debt of ¥3.77M.

How much cash does 3-d Matrix have on hand?

3-d Matrix reported ¥10.64M in cash and cash equivalents in its most recent financial results.

What is 3-d Matrix’s dividend yield?

3-d Matrix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services